atorvastatin calcium · Cmp Dev Llc · NDA 213260
Atorvaliq
Earliest generic entry, as listed
7 Jun 2037
Blocked by patent: US 11369567, US 11654106, US 11654106, US 11925704, US 12168069, US 12370136, US 12599553.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11369567 | product | 7 Jun 2037 |
| US 11654106 | product, use U-3613 | 7 Jun 2037 |
| US 11654106 | product, use U-3612 | 7 Jun 2037 |
| US 11925704 | product, use U-3853 | 7 Jun 2037 |
| US 12168069 | product | 7 Jun 2037 |
| US 12370136 | product | 7 Jun 2037 |
| US 12599553 | product | 7 Jun 2037 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213260 · 001 · RLD | suspension, oral | 20MG/5ML | 7 Jun 2037 |